ATR and posterior cortical atrophy: Concerning PCa, cotreatments showing superior antitumor efficacy in preclinical xenograft models include the combination of enzalutamide with the PARP inhibitor olaparib (Li et al., 2017) and the combination of darolutamide with the ATR inhibitor BAY 1895344 (Wengner et al., 2020).